KNP-101 / Kanaph Therapeutics, Dong-A - LARVOL DELTA

Kanaph Therapeutics to pursue partnering talks for AMD, cancer assets at BIO USA (Korea Biomedical Review) - "The company said discussions will focus on its lead pipeline assets, including KNP-301, a candidate for age-related macular degeneration (AMD), and KNP-101, an immuno-oncology therapy...The company said it has received requests for partnering meetings from more than 20 pharmaceutical and biotechnology companies ahead of BIO USA."

Preclinical • Oncology • Wet Age-related Macular Degeneration

Rational design of a repeated-dosing schedule for KNP-101 guided by IFN-γ regulation (AACR 2026) - "Our results demonstrate that the kinetics of IFN-γ regulation differ between systemic and tumor compartments, as well as between species, providing valuable insight for the rational design of IL-12-based immunotherapy."

IO biomarker • Oncology • CD34 • IFNG • IL12A

Overcoming systemic toxicity of IL-12-based immunotherapy by tumor-targeting and IL-12 attenuation (AACR 2025) - "KNP-101 exhibited a wide therapeutic window, by showing potent anti-tumor activities and significantly improved safety profiles. These attributes position KNP-101 as a promising therapeutic option for patients facing resistance to current cancer therapies."

IO biomarker • Oncology • IFNG • IL12A

Overcoming systemic toxicity of IL-12-based immunotherapy by tumor-targeting and IL-12 attenuation (SITC 2022) - "Our KNP-101 has a widen therapeutic window by maintaining potent anti-tumor activities and showing much improved safety profiles. We hope that KNP-101 can benefit patients in the future who suffer from primary and acquired resistance of the current anti-PD-1/PD-L1 treatments."

IO biomarker • Oncology • IFNG • IL12A